Evidence map›Paper›PMID 40510503›Full record

ArticlePathology oncology research : POR2025

Case Report: Flow cytometric differential diagnosis of a peripheral T-cell lymphoma, NOS with complete loss of CD45 and dim expression of CD3.

Gábor Szalóki, Ágota Szepesi, Ilona Tárkányi, Ágnes Márk, Csilla Kriston, Anna Hunyadi, Réka Mózes, Gábor Barna

Abstract readCase Reports
In one paragraph

Article in Pathology oncology research : POR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gábor SzalókiDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Ágota SzepesiDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Ilona TárkányiDepartment of Internal Medicine and Haematology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
Ágnes MárkDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Csilla KristonDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Anna HunyadiDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Réka MózesDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Gábor BarnaDepartment of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peripheral T-cell lymphomas (PTCLs) are a group of non-Hodgkin lymphomas originating from mature T-lymphocytes. Despite encompassing several well-defined entities, about 25% of the PTCLs do not fulfill the requirements of any of the subcategories. These diseases are classified as PTCL, not otherwise specified (PTCL, NOS), and often associated with poor prognosis. Hereby we present a case of a female patient, diagnosed with PTCL, NOS from her skin biopsy specimen. Besides histology and immunohistochemistry, flow cytometry was used for phenotyping and staging (peripheral blood, bone marrow). Pathologic T-cells were found in all the investigated tissues, with a very unusual CD45 negative and surface CD3 dim immunophenotype. For proper differential diagnosis, we determined several markers with immunohistochemistry (CD3, CD4, CD7, CD8, CD30, PD1, Ki-67) and flow cytometry: (CD2, cytoplasmic CD3, surface CD3, CD4, CD5, CD7, CD8, CD9, CD10, CD19, CD20, CD26, CD34, CD38, CD45, CD48, CD56, CD99, CD123, surface TRBC1, cytosplasmic TRBC1, surface TRBC2, cytoplasmic TRBC2, MPO, TdT, Igκ, Igλ). Here we discuss the difficulties of the differential diagnostic process and highlight some potential pitfalls of flow cytometric analysis of the pathologic T-cells with such a rare immunophenotype. Despite several determined markers, the disease characteristics did not meet the criteria of any PTCL subtype, therefore the diagnosis remained PTCL, NOS. Due to the aggressive course of the disease, we lost the patient within 1 year after the diagnosis.

Indexed as

Biomarkers, TumorCD3 ComplexLeukocyte Common AntigensLymphoma, T-Cell, PeripheralDiagnosis, DifferentialFemaleFlow CytometryHumansImmunophenotypingPrognosisBiomarkers, TumorCD3 ComplexLeukocyte Common AntigensPTPRC protein, humandifferential diagnosisflow cytometryimmunophenotypeNOSperipheral T-cell lymphomaPTCL

Identifiers

PMID40510503
PMCPMC12158790

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.